Most Viewed

Recent Activities by Topic

  • VIDEO FAQ: Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML - N. Daver, MD (6:03) - Posted 04/22
  • VIDEO FAQ: In this setting of the COVID-19 pandemic, will clinical trials continue to enroll patients? - D. Pollyea, MD (1:59) - Posted 04/08
  • VIDEO FAQ: What are the advantages and disadvantages of the different FLT3 inhibitors? - A. Perl, MD(1:57) - Posted 04/01
  • e-NEWSLETTER: Evolving Treatment Paradigms in AML: New Data and Clinical Trials That Could Change Clinical Practice - N. Daver, MD - Posted 02/17
  • Additional activities...
  • PODCAST: What are the most important prognostic factors to consider in AML? - P. Desai, MD (2:19) - Posted 12/05
  • VIDEO FAQ: How likely is it for patients with MDS to transform to AML? - J. Park, MD (3:33) - Posted 11/07
  • VIDEO FAQ: What are the practical issues in FLT3 testing as it relates to PCR vs. NGS? - A. Perl, MD (3:18) - Posted 10/10
  • VIDEO FAQ: What are the latest guidelines for molecular testing in AML? - J. Patel, MD (1:56) - Posted 07/24
  • Additional activities...


MediCom Worldwide, Inc. would like to recognize and thank the following companies for their educational support of Managing in 2018-2019

  • Agios Pharmaceuticals, Inc.
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Helsinn Healthcare SA
  • Jazz Pharmaceuticals
  • Pfizer Inc.

MediCom Oncology Links

Please visit these other members of the MediCom Oncology family of sites.

Managing MDS Managing Myeloma The Practical Oncologist
Managing Lymphoma Partners in Pancreatic Cancer Emerging Solutions in Pain